Source: UNIV OF IDAHO submitted to NRP
DEVELOPING A NOVEL LIQUID-PHASE PLASMA DISCHARGE TECHNOLOGY FOR NONTHERMAL AND CONTINUOUS MILK PROCESSING
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
1027957
Grant No.
2022-67017-36315
Cumulative Award Amt.
$602,800.00
Proposal No.
2021-08178
Multistate No.
(N/A)
Project Start Date
Jan 1, 2022
Project End Date
Dec 31, 2025
Grant Year
2022
Program Code
[A1332]- Food Safety and Defense
Recipient Organization
UNIV OF IDAHO
875 PERIMETER DRIVE
MOSCOW,ID 83844-9803
Performing Department
Chemical & Biological Engr.
Non Technical Summary
There is an urgent global need to protect the health of children and other consumers by offering safely processed milk and milk products. However, thermal milk processing usually leads to unwanted changes in sensory attributes (due to overheating) and to alterations in bioactive milk nutrientswhich have significant health benefits.The goal of this project is to establish a green, nonthermal plasma-based milk processing technology that will be compact, easy to operate, and efficient in producing a safe product with well-preserved sensory and nutritional characteristics and extended shelf life. This advanced technique is built on a novel, continuous-flow, liquid-phase plasma discharge (CLPD) reactor that is hypothesized to effectively and efficiently inactivate pathogens as well as endogenous enzymes while preserving quality attributes of the raw milk. Specific objectives of this proposal include 1) evaluating and optimizing a novel CLPD reactor for microbial inactivation using raw milk and pasteurized milk challenged with individual and community pathogenic bacterial species, 2) identifying operating conditions of the CLPD process that optimally preserve the physicochemical and nutritional properties of milk within conditions that achieve satisfying microbial inactivation, and 3) developing an up-scaled CLPD prototype for continuousmilk processing and comparing its performance to the high-temperature-short-time pasteurization process. Successful completion of this project will lay the technical groundwork for revolutionizing the milk processing technology to produce a high-quality, nutritionally superior milk product at reduced cost and reduced energy usage. This work addresses the Program Area Priorities of NIFA Program A1332, i.e., "Develop and validate advanced and innovative technologies or processes for food processing, and cleaning and sanitation to effectively reduce the presence of surviving enteric pathogens" and "Develop and validate novel strategies for the effective control of persistent reservoirs of foodborne pathogens."
Animal Health Component
70%
Research Effort Categories
Basic
30%
Applied
70%
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
50134502020100%
Knowledge Area
501 - New and Improved Food Processing Technologies;

Subject Of Investigation
3450 - Milk;

Field Of Science
2020 - Engineering;
Goals / Objectives
The goal of this project is to establish a green, nonthermal plasma-based milk processing technology that will be compact, easy to operate, and efficient in producing a safe product with well-preserved sensory and nutritional characteristics and extended shelf life. Specific objectives of this proposal include 1) evaluating and optimizing a novel CLPD reactor for microbial inactivation using raw milk and pasteurized milk challenged with individual and community pathogenic bacterial species, 2) identifying operating conditions of the CLPD process that optimally preserve the physicochemical and nutritional properties of milk within conditions that achieve satisfying microbial inactivation in Objective 1), and 3) developing an up-scaled CLPD prototype for raw milk processing based on process optimization results, and comparing its performance to the high temperature/short time pasteurization.
Project Methods
Specific Objective 1:Develop and optimize the novel CLPD reactor for microbial inactivation using raw milk and pasteurized milk supplemented with defined individual and community pathogenic bacteria.Two lab-scale CLPD reactors will be fabricated to accommodate changes in the thickness and opening diameter of the dielectric plate according to the experimental design. In CLPD operation, the milk will be pumped through the reactor for treatment in continuous passing mode as the default. Raw milk and pasteurized milk added with individual/community pathogens will be the substrates used in the experiments. Five foodborne pathogens of concern in raw milk as well as two common spores' formers were selected to be added to the pasteurized milk individually and as a community in this project. For community pathogen tests, roughly equal abundance of these bacterial species supplemented pasteurized milk will be treated by CLPD and log CFU reduction for each species will be determined with selective medium respectively. Total bacterial count or TBC will be determined with plate count. Milk enzyme inactivation by CLPD treatment will be analyzed as the reduction for total and respective activities of alkaline phosphatase, lactoperoxidase and lipase, as major spoilage enzymes that are often used as inactivation indicators for thermal and nonthermal pasteurization. Treatment efficiency for microbial inactivation will be quantified as the ratio of log TBC reduction to total power input, and energy efficiency for the CLPD processing will be determined as energy consumption in kJ per kilogram milk treated. Fiveprocess parameters include 1) milk flow rate; 2) carrier gas (air) flow rate; 3) input power; 4) the thickness of quartz dielectric plate; and 5) the orifice diameter of the dielectric plate. Each treatment scenario will be performed using these five process parameters in various combinations to evaluate CLPD performance according to the following Partial Factorial experimental design, Central Composite Design (CCD) and Response Surface Methodology (RSM) for process optimization.To characterize plasma discharge and reactive species and reveal their relationships with bacterial inactivation and milk quality, plasma properties will be characterized using time resolved records of voltage and current andoptical emission spectroscopy (OES).The OES spectrum profiles collected at a microsecond timescale will reflect concentrations of reactive species ROS and RNS during the CLPD treatment period for the tested operating conditions. Large datasets from different operating conditions will be compared by correlating the reduction of bacteria and enzyme activities as individual and combined response variables to the ROS and RNS profiles in nanosecond-scale sequences and to process variables to model and verify the mechanism of etching for continuous microbial inactivation by CLPD. A large number of multiple nonlinear regressions will be performed to model and quantify the correlation of microbial inactivation with reactive species and each CLPD process parameter. This collection of regression models will help elucidate the possible dominant mechanism of etching and oxidation by reactive species/radicals and effect(s) of CLPD on bacterial/enzyme inactivation.Specific Objective 2:Within the operating conditions that achieved FDA PMO standard in microbial inactivation in Specific Objective 1, identify parameters of the CLPD process that optimally preserve the physicochemical and nutritional attributes of raw milk.To evaluate the effects of CLPD on raw milk, a range of the physicochemical and nutritional properties of raw milk will be analyzed and evaluated based onFDA Grade APMO, with all samplestaken before and after each treatment condition described inObjective 1 andanalyzed in triplicate.The CLPD-treated milk samples will be stored at 4oC for 16 days to assess storage life in sterile plastic bags, using and discarding one bag daily for each treatment.Samples will be shipped overnight to Eurofins-DQCI, LLC for nutrient analysis of 1) % total fat, 2) % lactose, 3) % true protein, 4) % solids-not-fat, 5) % other solids, 6) milk urea nitrogen (mg/dL), 7)fatty acids, 8)Vitamin A, 9)vitamin B12. Finally, oxidation of fats and oils will be measured as liberated iodine by iodometric titration, which is equivalent to the levels of peroxides present. A sensory panel will be conducted at WSU CNPF for the off-flavor evaluation of the CLPD treated milk.The physicochemical and nutritional properties of raw milk will be compared to matched raw milk treated with CLPD under the five process parameters. Within the context of samples that pass bacterial inactivation, optimal milk quality will be defined for each variable as the smallest deviation from raw milk prior to CLPD treatment. Amilk quality scorefor each microbial, chemical and physical characteristic will be defined based on raw milk and FDA Grade A PMO standard levels, and anoverall quality scorewill be defined based on the combined squared deviation of each variable from raw milk characteristics, for each operational condition of CLPD processing. Dimensional reduction methods such as principal component analysis (PCA) will be used to determine and rank the independent system variables that account for the largest variability in these data.Specific Objective 3:Developing an up-scaled CLPD prototype for raw milk processing based on process optimization results and comparing its performance with HTST processing using the equivalent processing approach.Scale-up and evaluate the prototype CLPD system will be conducted by two means, i.e., increasing flowrate and input power without changing the reactor size, or build a manifold system of the CLPD reactor consisting of several parallelly connected reactors without increasing the size of each reactor but handle multiple flows to increase throughput. In the first method, based on the optimal milk flowrate and input power determined in previous sections, much larger milk flowrates will be analyzed, including 2, 3, 4, and 5 times the previously determined optimal flowrate. If microbial inactivation does not meet FDA Grade A standard, in-series design of two reactors to integrate double treatment for higher flowrate and throughput will be implemented and evaluated. The input power for each experiment will be adjusted to ensure the occurrence of plasma discharge.For the 2nd method for scale-up, three reactors with the optimal design parameters (the thickness, δ, and opening diameter, ?, of the dielectric plate) powered with three-phase AC transformer will be evaluated or the purpose of proving the concept. Since all the CLPD reactors are connected in parallel, the electrical voltage received by each reactor will be the same, and the necessity of increasing flow rate can be avoided. Capacity wise, the prototype designed here has three times the previously determined optimal flowrate. Once the concept is approved, this configuration can be expanded to include more reactors to form a larger module handling higher flow rates. The system will be evaluated under the optimal combination of all variables determined in Objective 1. The treatment throughput capacity and energy consumption for each run will be calculated, and the results will be compared among the runs. Based on the data from the prototype operation, capital inputs and operating costs of a full-scale CLPD system for commercial processing of raw milk will be estimated. Technoeconomic data from these studies will be compared with those from the first up-scale method. Equivalent processing and Technical Economic Analysis to compare CLPD performance efficacy (energy efficiency and capital/running cost) to inactivate microorganisms and preserve quality attributes of raw milk relative to HTST milk pasteurization will be conducted.

Progress 01/01/24 to 12/31/24

Outputs
Target Audience:1. Research institutions and industries engaged in milk processing research 2. Ordinary citizens who are interested in the impact of nonthermal milk processing technologies 3. Nationally and internationally professional communities for promoting food processing and food safety Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?The project in this period has provided training and professional development for 1 PhD student, 1 postdoc, and 1 Master student. How have the results been disseminated to communities of interest?The results have been disseminated to the communities of interest through a conference presentation at the ASABE 117th Annual International Meeting,University of Idaho Institute for Health in the Human Ecosystem Annual Research Symposium,as well asseveral peer-reviewed journals. What do you plan to do during the next reporting period to accomplish the goals?The plan for next reporting period will be focused on milk quality examination and reservation, and mechanism of shelf life extension of milk.

Impacts
What was accomplished under these goals? In this periodwe investigated the efficacy of continuous-flow liquid plasma discharge (CLPD) treatment against four different bacterial strains: Shiga toxin-producing Escherichia coli (STEC), Salmonella, Staphylococcus aureus (S. aureus), and Listeria monocytogenes. These strains were chosen because they are associated with foodborne illnesses and have varying degrees of resistance to antimicrobial treatments. The objective was to evaluate the extent of microbial inactivation achieved by CLPD under different experimental conditions for each strain. Results showed that CLPD treatment significantly reduced the bacterial load of all four strains; however, the extent of inactivation varied between strains, reflecting differences in their inherent resistance mechanisms. Listeria monocytogenes and S. aureus were the most susceptible to CLPD. These strains achieved a 6-log reduction under relatively mild treatment conditions, which included a balanced combination of system power and liquid flow rate. The ease with which these strains were inactivated suggests a low threshold for oxidative damage induced by reactive oxygen and nitrogen species (RONS) generated during CLPD. Salmonella species showed significant reductions, reaching 6-log reductions, but required slightly more aggressive experimental conditions compared to Listeria and Staphylococcus. Salmonella required higher power levels and longer exposure times, indicating that it was moderately resistant to CLPD, likely due to its ability to resist oxidative stress and maintain cellular integrity under harsh conditions. STEC showed the highest resistance to CLPD treatment. The most aggressive experimental conditions, including the highest system power and extended exposure times, were required to achieve a 6-log reduction of STEC. The enhanced resistance of STEC suggests that its strong cell wall structure and efficientDNA repair mechanisms protect against the damaging effects of RONS. To optimize the antibacterial efficacy of Continuous-Flow Liquid Phase Plasma Discharge (CLPD) treatment, the impact of varying liquid flow rates was systematically investigated. Three distinct flow rates were selected for this study: 30 mL/min, 50 mL/min, and 70 mL/min. These flow rates were chosen to explore how the residence time of milk within the plasma treatment zone influences the extent of bacterial inactivation. The results revealed a clear inverse relationship between the liquid flow rate and the bacterial log reduction achieved. As the flow rate decreased, allowing milk to remain longer within the plasma field, a more substantial reduction in bacterial load was observed. Specifically, the lowest flow rate of 30 mL/min resulted in the most significant bacterial reduction, achieving a 7.2-log CFU decrease. This suggests that longer exposure to plasma discharge enhances the interaction between reactive species generated by the plasma and the bacterial cells, leading to more effective inactivation.Several physicochemical properties and plasma diagnostics were measured, including electrical characteristics, optical emission spectroscopy (OES), and the concentration of reactive oxygen and nitrogen species (RONS). A typical oscillogram of the applied voltage and discharge current, obtained using a Plasma 250 power supply, is shown in Figure. The oscillogram reveals multiple pulses, with maximum voltage and current amplitudes ranging from 5.2 to 6.8 kV, corresponding to an input power range of 180 to 320 W. OES measurements were conducted across a wavelength range of 200 to 900 nm to identify the reactive species generated during CLPD treatment. The OES spectrum, depicted in Figure X, indicates the presence of various excited species. A significant emission peak at 777 nm corresponds to atomic oxygen (O), with additional peaks at 844 nm indicating further oxygen emissions. The spectrum also shows nitrogen emissions, with a prominent peak at 656 nm for hydrogen alpha (Ha) and multiple nitrogen-related vibrational bands, reflecting the strong presence of nitrogen species within the plasma. These peaks are consistent with the use of air as the working gas in the plasma discharge, contributing to the generation of both reactive nitrogen species (RNS) and reactive oxygen species (ROS). These findings provide crucial insights into the active species produced during CLPD treatment and their roles in the microbial inactivation processes observed in treated milk.

Publications

  • Type: Peer Reviewed Journal Articles Status: Published Year Published: 2023 Citation: Sheng, H., S. Wu, Y. Xue, W. Zhao, A. B. Caplan, C. J. Hovde. S. A. Minnich. 2023. Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance. PLoS ONE, 18(9): e0291520. https://doi. org/10.1371/journal.pone.0291520.
  • Type: Peer Reviewed Journal Articles Status: Published Year Published: 2024 Citation: 3. #Sheng, H., #R. Ndeddy Aka, *S. Wu. 2024. Lipopolysaccharide Core Truncation in Invasive Escherichia coli O157:H7 ATCC 43895 Impairs Flagella and Curli Biosynthesis and Reduces Cell Invasion Ability. International Journal of Molecular Sciences, 25:9224. https://doi.org/ 10.3390/ijms25179224.
  • Type: Peer Reviewed Journal Articles Status: Published Year Published: 2024 Citation: Mukhtar, A., S. Saqib, D. Mohotti, R.J. Ndeddy Aka, M.M. Hossain, E. Agyekum-Oduro, *S. Wu. 2024. Non-thermal plasma-catalytic processes for CO2 conversion toward circular economy: fundamentals, current status, and future challenges. Environmental Science and Pollution Research, https://doi.org/10.1007/s11356-024-34751-3.
  • Type: Peer Reviewed Journal Articles Status: Published Year Published: 2024 Citation: Hossain, MM., D. Mohotti, A. Mukhtar, S. Saqib, B. Miller, J. Zhu, *S. Wu. 2024. Investigating iron removal from wastewater and simultaneous iron oxide catalyst synthesis by dielectric barrier discharge. Journal of Water Process Engineering, 65:105893.
  • Type: Peer Reviewed Journal Articles Status: Published Year Published: 2023 Citation: 8. #Hossain, MM., #R. Ndeddy Aka, YS. Mok, *S. Wu. 2023. Investigation of silver nanoparticle synthesis with various nonthermal plasma reactor configurations. Arabian Journal of Chemistry, 16(10):105174. https://doi.org/10.1016/j.arabjc.2023.105174.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2024 Citation: Yuan, Y., H. Sheng, S. Deng, D. Mohotti, T. Booker, A. Mukhtar, S. Wu. 2024. Continuous Inactivating Shiga-toxin Producing E. coli in Milk By a Liquid-phase Plasma Process. ASABE 117th Annual International Meeting. Paper#: 2401484. Anaheim, CA. July 28-31, 2024.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2024 Citation: S. Wu, Y. Yuan, H. Sheng, MM. Hossain. NIFA Project Directors Annual Meeting for Joint Project Directors Meeting for Food Safety and Defense (A1332) and Mitigating Antimicrobial Resistance Across the Food Chain (A1366). Long Beach, CA, July 13-14, 2024.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2024 Citation: Y. Yuan, H. Sheng, T. Booker, D. Mohotti, S. Wu. Nonthermal and Continuous Milk Processing Using a Novel Liquid-Phase Plasma Discharge Technology. University of Idaho Institute for Health in the Human Ecosystem Annual Research Symposium, April 8, 2024.


Progress 01/01/23 to 12/31/23

Outputs
Target Audience:1. Research institutions and industries engaged in milk processing research 2. Ordinary citizens who are interested in the impact of nonthermal milk processing technologies 3. Nationally and internationally professional communities for promoting food processing and health Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?The project in this period has provided training and professional development for 1 PhD student, 1 postdoc, and 1 undergraduate researcher. How have the results been disseminated to communities of interest?The results have been disseminated to the communities of interest through a conference presentation at the ASABE 116th Annual International Meeting and submitting a journal manuscript to Frontiers in Microbiology. What do you plan to do during the next reporting period to accomplish the goals?In the next period, wewill continue to test the inactivation of 4 food pathogens-supplemented milk to find operational conditions that can result in at least 5-6 logs of inactivation for each pathogen in milk. We will also be working onidentifying operating conditions of the CLPD process that optimally preserve the physicochemical and nutritional properties of milk within conditions that achieve satisfying microbial inactivation with the lowest energy consumption.

Impacts
What was accomplished under these goals? During this period, amatrix of more than 20 unique operating conditions of CLPD processthat varied in voltage at discharge, input power, gas, and milk flow rates were used for nonthermal processing of commercially unpasteurized raw milk purchased from a local food coop. The design/operating parameters that achieved complete inactivation of total bacteria in the preliminary experiments included applied voltage at discharge: 780 V; input power: 250 W; air (carrier gas) flow rate: 0.2 standard liter per minute (SLPM); milk flow rate: 50 ml/min passing throughthe reactor system. For reactor design,the thickness of the quartz dielectric plate, δ = 3.2 mm; the dielectric plate opening, ? = 1.0 mm; and the internal diameter of the reactor, D = 12.7 mm was used. Continuous and stable plasma discharges were observed at both discharge points (at dielectric plate orifices) of the 2nd CLPD reactor as the milk flowed through. The raw milk was subjected to one single pass through the CLPD process, during which the effective contact time for milk with the plasma channel was estimated to be 6 milliseconds. At the end of treatment, the bulk milk temperature was 41.5°C. As compared to LTLT pasteurization which heats the same raw milk to 63°C for 30 minutes and HTST (72°C for 15 seconds), the CLPD exposure time is substantially shorter in the continuous-flow mode at a much lower processing temperature. In-series connection of two reactors will be studied for each one and combined inactivation efficiency. Results showed thatCLPD-treated raw milk had the highest values of true protein and solids-not-fat (lactose, caseins, whey, minerals, ash). Percentages of lactose, other solids (total solids minus fat and protein), milk urea nitrogen (a correlate of milk fat globule membrane or MFGM damage), and fatty acid components of CLPD-treated raw milk showed ignorable difference as compared to those in untreated raw milk and pasteurized milk samples. The slight increase in pH of CLPD-treated milk could be attributed to the stripping of dissolved CO2 in milk, but not to the production of unwanted inorganic ions which would reduce the pH. Although these data were derived from a single combination of operating conditions, all measured fatty acidsand physicochemical parameters were consistently unchanged from those of untreated raw milk and pasteurized milk.In addition, the forced passing of milk through two small orifices and the simplified one-pass continuous operation for bulk volumes will likely eliminate the need for homogenization and reduce scale-up costs for commercialization. Five typical pathogens in milk have been selected and collected to supplement pasteurized milk for CLPD treatment, including 1.Listeria monocytogenes, 2.Shiga-toxin producing E. coli (STEC), 3.Salmonella, 4.S. aureus, and 5.Bacillus cereus. Using the optimal condition identified with raw milk and E. coli (50 ml/min and 250 W), the log reduction for these five species is between 1-3 logs, signaling that the pathogens are more resistant to CLPD treatment and oxidation potential.In-series connection of two CLPD reactors have been studied and it was found that the trend for E. coli inactivation followed the addition relationship for log reduction. For example, at 100 ml/min flow rate, one reactor achieved 1.2 logs, while two achieved a little more than double at 2.9 logs of reduction for E. coli in milk. Further work in process design and optimizationis needed to improve pathogen inactivation efficiency.

Publications

  • Type: Conference Papers and Presentations Status: Published Year Published: 2023 Citation: Yuan, Y., H. Sheng, S. Deng, D. Mohotti, S. Wu. 2023. Nonthermal milk processing and quality preservation by continuous liquid plasma discharge process. ASABE 116th Annual International Meeting. Paper#: 2301501. Omaha, NE. July 9-12, 2023.
  • Type: Journal Articles Status: Submitted Year Published: 2024 Citation: Yuan Yuan, Shaobo Deng, Haiqing Sheng, MD Mokter Hossain, Robinson Junior Ndeddy Aka, Continuous inactivation of E. coli by air-activated liquid-phase plasma discharge. Submitted to Frontiers in Microbiology.


Progress 01/01/22 to 12/31/22

Outputs
Target Audience: 1. Research institutions and industries engaged in milk processing research 2. Ordinary citizens who are interested in the impact of nonthermal milk processing technologies 3. Nationally and internationally professional communities for promoting food processing and health Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?The project in this period has provided training and professional development for 1 Master's student, 1 postdoc, and 2 undergraduate researchers. How have the results been disseminated to communities of interest?The results have been disseminated to the communities of interest through conference presentations at the University of Idaho Institute for Health in the Human Ecosystem Annual Research Symposium, University of Idaho Undergraduate Research Symposium, Idaho INBRE Statewide Research Conference, and the ASABE 115th Annual International Meeting. What do you plan to do during the next reporting period to accomplish the goals?In the next year, the novelCLPD processing system will be evaluatedfor microbial inactivation using raw milk and pasteurized milk supplemented with defined individual and community pathogenic bacteria.

Impacts
What was accomplished under these goals? During this year, the work has been focused on the evaluation ofthe inactivation of E. coli (as a template microbe) by the novel established CLPD reactor to set the bottom line for the proposed second-generation CLPD processfor microbial/pathogen inactivation and the effluent quality of the liquid. First, a second-generationCLPD process was set up with a polycarbonate material reactor body with one high-voltage electrode and two ground electrodes, separated by two dielectric plates. These dielectric plates have a 1 mmopening in the center to concentrate the generated electrons during discharge so that the E. coli solution passing through the system is processed at least once and uniformly. Other parts in the CLPD treatment reactor system simplyinclude a peristaltic pump, a power supply, and a high-voltage AC transformer.To evaluate the process efficiency for E. coli inactivation and determine the significant process parameters that affect the disinfection ability of E. coli in water, a two-level partial factorial design is used. Four process parameters were selected according to preliminary experiments: conductivity (adjusted by adding NaCl to the initial E. coliinoculatedwater, 300-1000 μs/cm), applied power (determined by adjusting the variac transformer, 150-250 Watt), water flow rate (controlled by the peristaltic pump controller, 40-80 ml/min), and gas flow rate (controlled by a mass flow controller in standard liters per minute, 0.2-0.5 L/min). Asolution with a concentration of 2*107CFU/L E. coli water was used for each experimental run andpumped through the reactor in acontinuous passing mode based on the set liquid flow rate. At the end of each run, a 15 ml sample was taken, and the voltage, temperature, current, and power were recorded. The conductivity, pH, and concentration of CFU, nitrate ions (NO3- & NO2-), hydrogen peroxide (H2O2), and log reduction of three replicatesamples from each experimental run were measured and/or calculated. The resultsanalyzed with the Design-Expert softwaredetermine the statistical significance of each process parameter. Only applied plower and liquid flow rate out of the fourparameters were found to result ina p-value <0.05 which can be interpreted as the significantprocess parameters for E. coli inactivation by CLPD. At 250 watts, a liquid flow rate lower than 60 ml/min can achieve 6 or higher log reduction. On the other hand, at a 60 ml/min liquid flow rate, power higher than 250 watts can also achieve a 6-log reduction or higher. The pictures obtained by scanning electron microscope (SEM) revealed thatthe surface of the E. coli cells without plasma treatment is smooth, and the bacteria have a complete cell structure. After plasma treatment, the E. coli cell structure was severely damaged, the cell membrane was ruptured, and clumps were aggregated at the same time, the cell shape became smaller and irregular, and the permeability changed, indicating that the bacteria had died. Experimental results show that CLPD has a significant damaging effect on E. colicell structure. To optimize the two significant parameters, liquid flow rate and applied power, a central composite design (CCD) was used to find the optimal levels at a center between the five different levelsfor each of the individual variables, Surface response plots and quadratic equations for modeling the total bacterial inactivation rate and energy efficiency as the response variables were analyzed by the Design-Expert® software. Optimization shows that thehighest energy efficiency is achieved whenthe liquid flow rate is 52.3 mL/min and the system power of 250 watts. Taking the removal of 6 logs of Escherichia coli as the process standard, the lowest energy consumptionis 7.6 J/mL, which is among the lowest levels found in the literature. Overall, our findings have proved that CLPD is very promising in continuous E.coli and microbial inactivation with very short treatment time and not to cause significant change in water/liquid quality.

Publications

  • Type: Conference Papers and Presentations Status: Published Year Published: 2022 Citation: Yuan, Y., S. Deng, H. Sheng, R. Ndeddy Aka, L. Zhu, D. Mohotti, S. Wu. 2022. Nonthermal Milk Pasteurization by Continuous-Flow Liquid Phase Plasma Discharge. ASABE 115th Annual International Meeting. Paper#: 2200905. Houston, TX. July 17-20, 2022.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2022 Citation: Stachofsky L., Y. Yuan, J. Johnson, S. Wu. Production of plasma activated water as a green disinfectant for E. coli inactivation. University of Idaho Institute for Health in the Human Ecosystem Annual Research Symposium, April 7, 2022.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2022 Citation: Schoth, S., S. Wu, A. Nasir, Y. Yuan. 2022. Continuous inactivation of E. coli by liquid-phase plasma discharge. University of Idaho Undergraduate Research Symposium, April 25, 2022.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2022 Citation: Stachofsky, L., Y. Yuan, S. Wu. Evaluation of plasma activated water as a green disinfectant for E. coli inactivation. 2022 Idaho INBRE Statewide Research Conference. Moscow, ID. August 1-3, 2022.